Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 10, 2006, Pages 1475-1481

  Levi, Z ^a   Rozen, P ^a,c,d   Hazazi, R ^a   Vilkin, A ^a   Waked, A ^a   Maoz, E ^b   Birkenfeld, S ^c   Niv, Y ^a,c  

^a RABIN MEDICAL CENTER   (Israel)

^b CLALIT HEALTH SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; FAMILIAL CANCER; FECES ANALYSIS; FEMALE; HEMOGLOBIN ANALYSIS; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

AGED; COLONOSCOPY; COLORECTAL NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 33750441860     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03152.x     Document Type: Article

References (14)

1. Rozen P, Levin B, Young GP. Who is at risk from familial colorectal cancer and how can they be managed? In: Rozen P, Young GP, Levin B, Spann SJ, eds. Colorectal Cancer in Clinical Practice, 2nd edn. London: Taylor and Francis, 2005: 67-84.
2. Offit K, Brown K. Quantitating familial cancer risk: a resource for clinical oncologists. J Clin Oncol 1994; 12: 1724-36.
3. Dove-Edwin I, Sasieni P, Adams J, Thomas HJW. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Br Med J 2005; 331: 1047-52.
4. Itzkowitz SH. Colonic polyps and polyposis syndromes. In: Feldman M, Friedman LS, Sleeisenger MH, eds. Gastrointestinal and Liver Disease, 7th edn. Philadelphia: Saunders, 2002: 2178.
5. Young GP, Rozen P, Levin B. How should we screen for early colorectal neoplasia? In: Rozen P, Young GP, Levin B, Spann SJ, eds. Colorectal Cancer in Clinical Practice, 2nd edn. London: Taylor and Francis, 2005: 97-130.
6. Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical fecal occult blood test is more efficient for detecting significant colorectal neoplasia than is a sensitive guaiac test. Aliment Pharmacol Ther 2006; 23: 1359-64.
7. Caffarey SM, Broughton CIM, Marks CG. Faecal occult blood screening for colorectal neoplasia in a targeted high-risk population. Br J Surg 1993; 80: 1399-400.
8. Leiberman DA, Holub J, Eisen G, Kraemer D, Morris CD. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005; 62: 875-83.
9. Young GP. Fecal immunochemical tests (FIT) vs office-based guaiac fecal occult blood test (FOBT). Pract Gastroenterol 2004; 18: 46-56 (http://www.practicalgastro.com).
10. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-26.
11. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006; 12: MT27-32.
12. Castiglione G, Grazzini G, Miccinesi G, et al. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 2002; 9: 99-103.
13. Bampton PA, Sandford JJ, Cole SR, et al. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology. Gut 2005; 54: 803-6.
14. Schoenfeld PS, Fincher RK for the Military Colorectal Cancer Screening Trials Group. Colonoscopic surveillance of patients with a family history of colon cancer and a history of normal colonoscopy: is a five-year interval between colonoscopies appropriate? Clin Gastroenterol Hepatol 2003; 1: 310-4.